Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial-Reference-Cited by-同舟云学术

Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial

Published:2024-09-11 Issue:1 Volume:15 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Zhang Bo^ORCID,Fong Youyi,Fintzi Jonathan,Chu Eric,Janes Holly E.,Kenny Avi,Carone Marco^ORCID,Benkeser David^ORCID,van der Laan Lars W. P.,Deng Weiping,Zhou Honghong,Wang Xiaowei,Lu Yiwen,Yu Chenchen,Borate Bhavesh,Chen Haiyan,Reeder Isabel^ORCID,Carpp Lindsay N.^ORCID,Houchens Christopher R.,Martins Karen,Jayashankar Lakshmi,Huynh Chuong,Fichtenbaum Carl J.^ORCID,Kalams Spyros^ORCID,Gay Cynthia L.^ORCID,Andrasik Michele P.,Kublin James G.,Corey Lawrence^ORCID,Neuzil Kathleen M.^ORCID,Priddy Frances,Das Rituparna,Girard Bethany,El Sahly Hana M.^ORCID,Baden Lindsey R.^ORCID,Jones Thomas,Donis Ruben O.^ORCID,Koup Richard A.,Gilbert Peter B.^ORCID,Follmann Dean^ORCID, , , , ,van der Laan Lars W. P.

Abstract

AbstractIn the phase 3 Coronavirus Efficacy (COVE) trial (NCT04470427), post-dose two Ancestral Spike-specific binding (bAb) and neutralizing (nAb) antibodies were shown to be correlates of risk (CoR) and of protection against Ancestral-lineage COVID-19 in SARS-CoV-2 naive participants. In the SARS-CoV-2 Omicron era, Omicron subvariants with varying degrees of immune escape now dominate, seropositivity rates are high, and booster doses are administered, raising questions on whether and how these developments affect the bAb and nAb correlates. To address these questions, we assess post-boost BA.1 Spike-specific bAbs and nAbs as CoRs and as correlates of booster efficacy in COVE. For naive individuals, bAbs and nAbs inversely correlate with Omicron COVID-19: hazard ratios (HR) per 10-fold marker increase (95% confidence interval) are 0.16 (0.03, 0.79) and 0.31 (0.10, 0.96), respectively. In non-naive individuals the analogous results are similar: 0.15 (0.04, 0.63) and 0.28 (0.07, 1.08). For naive individuals, three vs two-dose booster efficacy correlates with predicted nAb titer at exposure, with estimates -8% (-126%, 48%), 50% (25%, 67%), and 74% (49%, 87%), at 56, 251, and 891 Arbitrary Units/ml. These results support the continued use of antibody as a surrogate endpoint.

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41467-024-52348-9.pdf

Reference35 articles.

1. Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).

2. El Sahly, H. M. et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N. Engl. J. Med. 385, 1774–1785 (2021).

3. Benkeser, D. et al. Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial. Sci. Transl. Med. 15, eade9078 (2023).

4. Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43–50 (2022).

5. Huang, Y. et al. Stochastic interventional vaccine efficacy and principal surrogate analyses of antibody markers as correlates of protection against symptomatic COVID-19 in the COVE mRNA-1273 trial. Viruses 15, 2029 (2023).